Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Mar, Javier ^a,b   Soto Gordoa, Myriam ^a,b   Arrospide, Arantzazu ^a,b   Moreno Izco, Fermín ^c   Martínez Lage, Pablo ^d  

^a Clinical Management Unit   (Spain)

^b Health Services Research on Chronic Patients Network (REDISSEC)   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d Center for Research and Advanced Therapies   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CALIBRATION; DEATH; DISEASE DURATION; EPIDEMIOLOGICAL DATA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROGRAM FEASIBILITY; SIMULATION; SPAIN; TIME; VERY ELDERLY;

EID: 84928031620     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0079-9     Document Type: Article

References (40)

1. Cummings J. Alzheimer's disease diagnostic criteria: practical applications. Alzheimers Res Ther. 2012;4:35.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
3. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-28.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-27.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
6. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257-62.
7. Jack Jr CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765-75.
8. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960-9.
9. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957-65.
10. Bateman RJ, Klunk WE. Measuring target effect of proposed disease modifying therapies in Alzheimer's disease. Neurotherapeutics. 2008;5:381-90.
11. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-28.
12. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-42.
13. Budd D, Burns LC, Guo Z, L'Italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation. Clinicoecon Outcomes Res. 2011;3:189-95.
14. Mar. J, Arrospide A, Comas M. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. Value Health. 2010;13:69-76.
15. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S10-5.
16. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research group. Neurology. 2000;54:S4-9.
17. Karnon J, Stahl J, Brennan A, Caro JJ, Mar. J, Möller J, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value Health. 2012;15:821-7.
18. Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis. 2010;19:253-72.
19. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362-81.
20. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-800.
21. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly Jr ES, Cox NJ, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Internal Med. 2010;153:176-81.
22. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66:1447-55.
23. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: a Systematic Review of the Literature. Dement Ger Cogn Disord Extra. 2013;3:320-32.
24. Roman R, Comas M, Hoffmeister L, Castells X. Determining the lifetime density function using a continuous approach. J Epidemiol Community Health. 2007;61:923-5.
25. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-7.
26. Dodge HH, Shen C, Pandav R, De Kosky ST, Ganguli M. Functional transitions and active life expectancy associated with Alzheimer disease. Arch Neurol. 2003;60:253-9.
27. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27:533-45.
28. De Pedro-Cuesta J, Virués-Ortega J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F, et al. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurol. 2009;9:55.
29. Neuropathology Group of the Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicenter, community based population in England and Wales. Lancet. 2001;357:169-75.
30. Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. J Intern Med. 2014;275:229-50.
31. Kivipelto M, Solomon A. Preventive neurology: on the way from knowledge to action. Neurology. 2009;73:168-9.
32. Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis. 2010;20:689-97.
33. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013;169:737-43.
34. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6:1106-14.
35. Puliti D, Duffy SW, Miccinesi G, EUROSCREEN Working Group, De Koning H, Lynge E, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19:42-56.
36. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet. 2012;380:1441-3.
37. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385-93.
38. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379-88.
39. Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc. 2008;56:1424-33.
40. Brayne C. The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci. 2007;8:233-9.